PANTOPRAZOLE MAGNESIUM

Details

Stereochemistry	RACEMIC
Molecular Formula	2C16H14F2N3O4S.Mg
Molecular Weight	789.029
Optical Activity	( + / - )
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Mg++].COC1=C(OC)C(C[S+]([O-])C2=NC3=C([N-]2)C=C(OC(F)F)C=C3)=NC=C1.COC4=C(OC)C(C[S+]([O-])C5=NC6=C([N-]5)C=C(OC(F)F)C=C6)=NC=C4

InChI

InChIKey=RDRUTBCDIVCMMX-UHFFFAOYSA-N

InChI=1S/2C16H14F2N3O4S.Mg/c2*1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16;/h2*3-7,15H,8H2,1-2H3;/q2*-1;+2

HIDE SMILES / InChI

Molecular Formula	Mg
Molecular Weight	24.305
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C16H15F2N3O4S
Molecular Weight	383.37
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020987s050,022020s012lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11402494 | https://www.ncbi.nlm.nih.gov/pubmed/24301963

Pantoprazole is a proton pump inhibitor that inhibits gastric acid secretion and used for short-term treatment of erosive esophagitis associated with gastroesophageal reflux disease. Pantoprazole suppresses the final step in gastric acid production by covalently binding to the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. The binding to the (H+, K+)-ATPase results in a duration of antisecretory effect that persists longer than 24 hours. Pantoprazole is used for short-term treatment of erosion and ulceration of the esophagus for adults and pediatric patients 5 years of age and older caused by gastroesophageal reflux disease. It can be used as a maintenance therapy for long-term use after initial response is obtained, but there have not been any controlled studies about the use of pantoprazole past a duration of 12 months. Pantoprazole may also be used in combination with antibiotics to treat ulcers caused by Helicobacter pylori. Use of pantoprazole may increase the chance of developing infections such as pneumonia, particularly in hospitalized patients.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Potassium-transporting ATPase 38 Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18536934 \| https://www.ncbi.nlm.nih.gov/pubmed/8389196	Inhibitor 8504
Potassium-transporting ATPase 38 Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11402494	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Erosive esophagitis associated with gastroesophageal reflux disease 7 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020987s050,022020s012lbl.pdf	Primary		Approved 8583	PROTONIX Approved Use INDICATIONS AND USAGE. PROTONIX is a proton pump inhibitor indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD). Maintenance of Healing of Erosive Esophagitis. Pathological Hypersecretory Conditions Including ZollingerEllison Syndrome. Launch Date 2000
Zollinger-Ellison syndrome 17 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020987s050,022020s012lbl.pdf	Primary		Approved 8583	PROTONIX Approved Use INDICATIONS AND USAGE. PROTONIX is a proton pump inhibitor indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD). Maintenance of Healing of Erosive Esophagitis. Pathological Hypersecretory Conditions Including ZollingerEllison Syndrome. Launch Date 2000

C_max

Value	Dose	Co-administered	Analyte	Population
2.4 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20987lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		PANTOPRAZOLE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
4.8 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20987lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		PANTOPRAZOLE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20987lbl.pdf	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		PANTOPRAZOLE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 inducer 1087 substrate 1946	substrate 1193 inhibitor 2438	substrate 1388 inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MRP2 499 OAT3 747 CYP2C8 1057 CYP1A2 2153 CYP2A6 879 CYP2E1 1060 P-gp 1741 BCRP 910 CYP2C19 2057 OAT1 725 OATP1B1 1079 OATP1B3 961 OCT1 620 OCT2 779 OCT3 159 ALDH1 41 MATE2 267 MATE1 415 OATP2B1 157	CYP2C19 1119 P-gp 2052 sulfotransferases 39	CYP1A 59 CYP1A1 151 CYP2C 17

Drug as perpetrator

Target	Modality	Activity
ALDH1 41	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNTc3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	inconclusive [Activation 22.3872 uM]
OATP1B1 1095	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19139163/	likely
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6Ilx0Q0hFTUJMMTUwMiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	no [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTUwMiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	no [IC50 >10 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTUwMiJ9fQ%3D%3D	no [IC50 >10 uM]
MATE2 267	inhibitor 4027 Sources: https://pubs.acs.org/doi/10.1021/jm301302s \| https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	no [IC50 >500 uM]
CYP2C8 1117	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/15601807/	no
MRP2 625	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/15313923/	no
OATP2B1 162	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/	no
CYP2C19 2141	inhibitor 4027 Sources: https://go.drugbank.com/drugs/DB00213 \| https://drug-interactions.medicine.iu.edu/MainTable.aspx \| https://pubmed.ncbi.nlm.nih.gov/21795468/	weak [IC50 93 uM]
P-gp 1932	inhibitor 4027 Sources: https://go.drugbank.com/articles/A16156 \| https://pubmed.ncbi.nlm.nih.gov/11770010/	yes [IC50 17.9 uM]
OCT2 782	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/ \| https://pubs.acs.org/doi/10.1021/jm301302s	yes [IC50 2.8 uM]
OCT3 161	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/ \| https://pubs.acs.org/doi/10.1021/jm301302s	yes [IC50 22.9 uM]
OCT1 656	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/ \| https://pubs.acs.org/doi/10.1021/jm301302s	yes [IC50 30.8 uM]
OAT3 749	inhibitor 4027 Sources: https://go.drugbank.com/drugs/DB00213 \| https://pubmed.ncbi.nlm.nih.gov/25239859/	yes [IC50 4.45 uM]
MATE1 416	inhibitor 4027 Sources: https://pubs.acs.org/doi/10.1021/jm301302s \| https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE1MDIifX0%3D	yes [IC50 43.2 uM]
BCRP 985	inhibitor 4027 Sources: https://go.drugbank.com/articles/A16380 \| https://pubmed.ncbi.nlm.nih.gov/19076159/	yes [IC50 5.5 uM]
OAT1 730	inhibitor 4027 Sources: https://go.drugbank.com/drugs/DB00213 \| https://pubmed.ncbi.nlm.nih.gov/25239859/	yes [IC50 63.21 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/15258107/	yes [Ki 6.5 uM]
CYP1A 122	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=21 Page: (Pharm_P7) 21	yes
CYP1A1 272	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/11996015/	yes
CYP2C 37	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 Page: (Pharm_P7) 22	yes
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 Page: (Pharm_P7) 22	yes
MRP2 625	activator 342 Sources: https://pubmed.ncbi.nlm.nih.gov/15313923/	yes
OATP1B3 970	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes
OCT3 161	activator 342 Sources: https://pubmed.ncbi.nlm.nih.gov/21779389/	yes

Drug as victim

Target	Modality	Activity
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 \| https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.04d&code=C29346&ns=ncit&type=relationship&key=n75796996&b=1&n=0&vse=null Page: (Pharm_P7) 22, (ClinP_P1) 25	major
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 Page: (Pharm_P7) 22, (ClinP_P1) 25	major
CYP2C9 1193	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 Page: (Pharm_P7) 22, (ClinP_P1) 25	minor
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_pharmr_P7.pdf#page=22 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20987_Protonix_biopharmr_P1.pdf#page=25 Page: (Pharm_P7) 22, (ClinP_P1) 25	minor
P-gp 2052	substrate 4014 Sources: https://go.drugbank.com/articles/A16156 \| https://pubmed.ncbi.nlm.nih.gov/11770010/	yes
sulfotransferases 39	substrate 4014 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=102625707 \| https://pubmed.ncbi.nlm.nih.gov/9165689/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:7915	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7915
ChemicalBook	CB51025809	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB51025809
ChemicalBook	CB8129842	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8129842
eMolecules	902267	https://www.emolecules.com/cgi-bin/more?vid=902267
MolPort	MolPort-003-666-752	https://www.molport.com/shop/molecule-link/MolPort-003-666-752
MolPort	MolPort-005-933-577	https://www.molport.com/shop/molecule-link/MolPort-005-933-577

PubMed

Title	Date	PubMed
Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care.	2002-10-21	12381251
Factors associated with treatment failure of Helicobacter pylori infection in a developing country.	2002-10	12352294
Short-term therapeutic trial of proton pump inhibitors in suspected extraesophageal reflux.	2002-09	12395996
Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.	2002-08	12182745
Efficacy and tolerability of ranitidine bismuth citrate plus amoxycillin and clarithromycin as first- or second-line therapy to cure Helicobacter pylori infection.	2002-07-30	12143188
Proton pump inhibitors: an update.	2002-07-15	12152963
Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials.	2002-07-15	12119060
Long-term clinical outcome of elderly patients with reflux esophagitis: a six-month to three-year follow-up study.	2002-07-13	12115018
Early relief of upper gastrointestinal dyspeptic symptoms: a survey of empirical therapy with pantoprazole in Canadian clinical practice.	2002-07	12177723
Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.	2002-07	12152007
Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate.	2002-06-22	12077038
[Intravenous 3-day Helicobacter pylori eradication therapy is highly effective in patients with bleeding peptic ulcer].	2002-06-19	12069699
Persistent eradication of Helicobacter pylori after systemic politherapy associated with periodontal pockets treatment with metronidazole and calcium sulphate.	2002-06-18	12067080
[Correlation of Barrett's esophagus and colonic adenomas].	2002-06-09	12132329
Pantoprazole-induced recurrent anaphylactic shock.	2002-06	12094902
Intravenous proton pump inhibitors in the critical care setting.	2002-06	12072664
Stress-related mucosal disease in the critically ill patient: risk factors and strategies to prevent stress-related bleeding in the intensive care unit.	2002-06	12072662
Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition.	2002-06	12072661
A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial.	2002-06	12072599
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.	2002-06	12030958
Stability of pantoprazole in an extemporaneously compounded oral liquid.	2002-05-15	12040734
Gateways to clinical trials.	2002-05-01	11980386
Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study.	2002-05	12017345
Combination drug therapy for gastroesophageal reflux disease.	2002-05	11978171
Pantoprazole IV (Protonix IV).	2002-04-29	11981511
Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.	2002-04	12070410
Selective colonization by Helicobacter pylori of the deep gastric glands and intracellular canaliculi of parietal cells in the setting of chronic proton pump inhibitor use.	2002-04	11943964
Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers.	2002-04	11929403
Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test.	2002-03	11876710
Acid suppression in healthy subjects following lansoprazole or pantoprazole.	2002-03	11876695
Review article: rabeprazole-based therapy in Helicobacter pylori eradication.	2002-03	11849125
[Proton pump inhibitors: Pantoprazole].	2002-02	11979865
Nonallergic anaphylaxis to pantoprazole.	2002-02	11929432
Protonix. First i.v. proton pump inhibitor approved.	2002-02	11924161
Conformational analysis: a new approach by means of chemometrics.	2002-01-30	11926199
Enantiomeric determination of pantoprazole in human plasma by multidimensional high-performance liquid chromatography.	2002-01-05	11824393
The novel use of an intravenous proton pump inhibitor in a patient with short bowel syndrome.	2002-01	11743248
[Submicroscopic aspects of the mechanism of inhibitors of H+/K+-ATPase in gastric parietal cells].	2002	12353402
Clinical significance of the cytochrome P450 2C19 genetic polymorphism.	2002	12222994
Efficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux esophagitis and the influence of Helicobacter pylori infection on healing rate.	2002	12060043
[Microflora of gastric juice in patients after eradication of Helicobacter pylori and treatment with a proton pump inhibitor].	2002	12043311
Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial).	2001-12-17	11802510
Prophylaxis and treatment of non-steroidal anti-inflammatory drug-induced upper gastrointestinal side-effects.	2001-12	11827362
Proton pump inhibitors and gastric acid secretion.	2001-12	11774990
Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.	2001-12	11774936
Oral pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome.	2001-12	11773945
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.	2001-12	11770010
Cluster headache without autonomic symptoms?	2001-11	11903290
Pantoprazole.	2001-06-01	11402494
Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.	2001	11768559

Patents

Sample Use Guides

In Vivo Use Guide

Oral use: Short-Term Treatment of Erosive Esophagitis Associated With GERD: 40 mg Once daily for up to 8 weeks; Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome: 40 mg Twice daily IV: The recommended adult dose is 40 mg pantoprazole given once daily by intravenous infusion for 7 to 10 days

Route of Administration: Other

In Vitro Use Guide

To determine "ex vivo" gastric mucosa gastric acid secretion, pantoprazole (as DMSO solution diluted with serosal fluid) was added to membrane mucosa liquid in the bath tube. Pantoprazole final concentration in serosal fluidwas 5 mkM, incubation time -- 2.5h. Pantoprazole mediated gastric acid secretion inhibition is 24.3% at 5mkM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:58:13 GMT 2025` Edited by `admin` on `Mon Mar 31 18:58:13 GMT 2025`
Record UNII	1AL13B11R4
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PANTOPRAZOLE MAGNESIUM

Common Name

English

MAGNESIUM PANTOPRAZOLE

Preferred Name

English

Pantoprazole magnesium [WHO-DD]

Common Name

English

PANTOPRAZOLE HEMIMAGNESIUM

Common Name

English

Code System Code Type Description

FDA UNII

1AL13B11R4